Retatrutide vs Tirzepatide:
Key differences comparison

Phase 3 trial results

In TRIUMPH-1, the 12 mg dose of retatrutide produced an average of 28.3% body weight loss at 80 weeks, with participants who had a BMI of 35 or higher reaching up to 30.3% by week 104. Tirzepatide's own pivotal trial, SURMOUNT-1, showed an average of 20.9% body weight loss at 72 weeks on the 15 mg dose.

Dose-dependent response for both

Retatrutide's effect scales with dose: roughly 17.6% at 4 mg, 23.7% at 9 mg, and 28.3% at 12 mg over 80 weeks in TRIUMPH-1. Tirzepatide shows a similar dose-response pattern across its 5, 10, and 15 mg doses.

Why the gap may exist

Retatrutide's added glucagon receptor activity is thought to raise energy expenditure and increase fat burning in the liver on top of the appetite-reducing effects both peptides share through GLP-1 and GIP activation.

Retatrutide trends toward higher GI rates

In the TRIUMPH-4 trial, retatrutide's 12 mg dose was linked to higher rates of nausea and vomiting than tirzepatide, alongside heart rate increases reported most often in the first 24 weeks.

A side effect unique to retatrutide

Dysesthesia (an unusual skin sensation) has been reported in retatrutide trials at the 12 mg dose but has not been reported with tirzepatide, based on published trial data so far.

Shared contraindications

Both carry the same core warnings: a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Tirzepatide also lists a history of pancreatitis, while retatrutide's labeling flags severe renal impairment.

Tirzepatide's measured fat-to-lean ratio

In tirzepatide trial body-composition data, fat mass decreased by about 33.9% while lean mass decreased by about 10.9%, a ratio broadly in line with other calorie-deficit weight loss.

Retatrutide's glucagon activity is a theoretical edge

Glucagon receptor activity is thought to favor fat breakdown in the liver over muscle protein loss, which is why some researchers expect retatrutide to preserve relatively more lean mass. Head-to-head body-composition data to confirm this is still limited.

Resistance training and protein intake matter most

Research on GLP-1-class therapies consistently points to strength training and adequate protein as the biggest levers for preserving muscle, regardless of which peptide is used.

Tirzepatide brand-name pricing

Mounjaro and Zepbound typically list at over $1,000/month without insurance, though manufacturer savings cards can lower out-of-pocket cost significantly for eligible patients.

Retatrutide has no confirmed price yet

Since retatrutide isn't FDA-approved, there's no official brand pricing. Industry estimates suggest a monthly cost somewhere in the same range as tirzepatide once it reaches market, but that figure isn't confirmed.

Research-grade vial pricing

Research-grade retatrutide vials typically run about $43–$550 depending on size, and research-grade tirzepatide about $41–$400. These are research chemical products, not FDA-approved medications, and quality varies by supplier.

Compounding rules tightened in 2026

Tirzepatide is off the FDA shortage list, so large-scale compounding is no longer broadly allowed and is now mostly limited to patients with a documented medical need. Retatrutide was never eligible for compounding since it isn't an approved drug.

No official conversion exists

The two peptides aren't dosed on a 1:1 basis, and because retatrutide is still investigational, there's no approved clinical guidance on converting a tirzepatide dose to an equivalent retatrutide dose.

A fresh titration is the norm

Most people researching a change start at the lowest end of the new peptide's dose range and re-titrate upward gradually, the same way anyone starting a GLP-1-class peptide for the first time would.

Side effects can restart

Because retatrutide activates an additional receptor pathway, GI side effects and heart rate changes can appear again during re-titration even after a person was fully adjusted to tirzepatide.

Tirzepatide has years of real-world monitoring

Tirzepatide has been FDA-approved and prescribed since 2022 (Mounjaro) and 2023 (Zepbound), giving it years of post-market safety monitoring that retatrutide, still in trials, hasn't had the chance to accumulate.

Similar core warnings, more GI signal for retatrutide

Both carry warnings around thyroid C-cell tumors (seen in animal studies) and MEN2 syndrome. Trial data so far points to somewhat higher rates of nausea and vomiting with retatrutide, plus a heart-rate increase most common in the first 24 weeks.

No FDA review yet for retatrutide

Eli Lilly has not yet filed for FDA approval of retatrutide as of mid-2026, with a planned submission expected in early 2027. Until that review is complete, its long-term safety profile remains less established than tirzepatide's.

If maximum average weight loss is the research goal

Retatrutide's triple-receptor mechanism is linked to the largest average weight loss reported in a Phase 3 obesity trial so far, at the cost of no FDA approval and a shorter data history.

If an approved, available option matters more

Tirzepatide is FDA-approved, prescribable today, and backed by years of real-world safety monitoring, with a somewhat lower average effect size than retatrutide's early trial results.

Neither is a casual research chemical

Tirzepatide is an FDA-approved prescription drug. Retatrutide remains investigational. Research-grade versions of either sold online are labeled for research only and are not intended for self-administration.